Dr. McNorgan Discusses Hemostemix's Stem Cell Technology and Potential with Elon Musk's Neuralink

written by InvestorNews | June 1, 2023

In this InvestorIntel interview, Tracy Weslosky talks with Hemostemix Inc.'s (TSXV: HEM | OTCQB: HMTXF) Advisory Board Member Dr. Chris McNorgan, Ph.D. about why Hemostemix's NCP-01 (Neural Cellular Precursors) technology would be of interest to a company like Neuralink.

With Elon Musk's brain implant company Neuralink recently receiving FDA approval for human trials, Dr. McNorgan explains how NCP-01 can potentially assist in all phases of the implantation process, including mitigating complications and ensuring proper functionality of the brain implants.

Neurons do not naturally regenerate, causing lifelong problems when damaged. With the potential to regenerate neuronal cells, Dr. McNorgan discusses how Hemostemix's NCP-01 technology can also help restore brain functionality in patients suffering from progressive dementia.

Dr. McNorgan directs the Computational Cognitive Neuroscience (CCN) laboratory at the University of Buffalo. His research focuses on computational cognitive neuroscience, developing computer models to simulate how the brain functions, and is directly relatable to neural electrode-based implantation.

Dr. McNorgan estimates the current market for assistive technologies related to brain signal interception and decoding

is estimated to be around $36.5 billion, but the potential market is much larger once the technology is perfected.

The applications of Hemostemix's technology extend beyond assistive technologies, including addressing conditions like blindness, hearing loss, and dementia.

To access the full InvestorIntel interview, click here

Don't miss other InvestorIntel interviews. Subscribe to the InvestorIntel YouTube channel by clicking here

About Hemostemix Inc.

Hemostemix is an autologous stem cell therapy company, founded in 2003. A winner of the World Economic Forum Technology Pioneer Award, the Company has developed, patented, and is scaling a patient's blood-based stem cell therapeutics platform that includes angiogenic cell precursors, neuronal cell precursors, and cardiomyocyte cell precursors. The Company develops cell therapy products from the patient's own blood, which is a non-invasive source of therapeutic cells. Its lead product is ACP-01, an autologous cell therapy, which is in FDA Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia. Its second product is NCP-01, used to help rebuild neuronal pathways in the brain after injury or disease.

To learn more about Hemostemix Inc., click here

Disclaimer: *Hemostemix Inc. is an advertorial member of InvestorIntel Corp.*

This interview, which was produced by InvestorIntel Corp., (IIC), does not contain, nor does it purport to contain, a

summary of all the material information concerning the “Company” being interviewed. IIC offers no representations or warranties that any of the information contained in this interview is accurate or complete.

This presentation may contain “forward-looking statements” within the meaning of applicable Canadian securities legislation. Forward-looking statements are based on the opinions and assumptions of the management of the Company as of the date made. They are inherently susceptible to uncertainty and other factors that could cause actual events/results to differ materially from these forward-looking statements. Additional risks and uncertainties, including those that the Company does not know about now or that it currently deems immaterial, may also adversely affect the Company’s business or any investment therein.

Any projections given are principally intended for use as objectives and are not intended, and should not be taken, as assurances that the projected results will be obtained by the Company. The assumptions used may not prove to be accurate and a potential decline in the Company’s financial condition or results of operations may negatively impact the value of its securities. Prospective investors are urged to review the Company’s profile on Sedar.com and to carry out independent investigations in order to determine their interest in investing in the Company.

If you have any questions surrounding the content of this interview, please contact us at +1 416 792 8228 and/or email us direct at info@investorintel.com.